Effectiveness of acetylcysteine in first line therapy to cure Helicobacter pylori. Pilot study. - ND
- Conditions
- peptic, duodenal and gastric ulcer with Helicobacter pylori infectionMedDRA version: 9.1Level: LLTClassification code 10051790MedDRA version: 9.1Level: LLTClassification code 10065231
- Registration Number
- EUCTR2009-011978-15-IT
- Lead Sponsor
- POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
both genders, age > 18 years, infection from Helicobacter pylori, at gastroscopy or 13C urea breath test.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Verified allergies to the acetylcysteine or to the antibiotics to cure Helicobacter pylori, pregnancy, nursing.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: Effectiveness of acetylcysteine in first line therapy to cure Helicobacter pylori. Due to lytic action on the gastric mucus, the administration of acetylcysteine in the 7 preceding days the first line therapy would allow a best aggression of the Helicobacter from the usual antibiotic.;Secondary Objective: ND;Primary end point(s): Helicobacter pylori eradication
- Secondary Outcome Measures
Name Time Method